Quick Answer
MAIA Biotechnology, Inc. reported Net Income of -$22.40 million for fiscal year 2025.
MAIA Biotechnology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$22.40M +3.7% |
-$23.25M | — | — | — | — |
| Diluted EPS | -$0.70 +33.3% |
-$1.05 +29.5% |
-$1.49 +14.9% |
-$1.75 +26.2% |
-$2.37 | — |
| Total Assets | $9.70M -4.4% |
$10.16M +34.2% |
$7.57M -37.1% |
$12.02M +6.1% |
$11.33M | — |
| Stockholders Equity | $2.38M -34.6% |
$3.63M +661.2% |
$477.5K -94.4% |
$8.51M -7.3% |
$9.18M +668.0% |
-$1.62M |
| R&D Expense | — | $10.01M -9.9% |
$11.11M +24.4% |
$8.93M +155.5% |
$3.50M | — |
| Operating Income | -$24.27M -43.1% |
-$16.96M +16.0% |
-$20.18M -24.8% |
-$16.18M -107.7% |
-$7.79M | — |
| Shares Outstanding | 38.62M +47.7% |
26.16M +54.0% |
16.99M +55.0% |
10.96M +44.4% |
7.58M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.90M | -225.4% | -66.5% |
| Diluted EPS | September 30, 2025 | -$0.27 | -145.5% | -50.0% |
| Total Assets | September 30, 2025 | $11.78M | +27.5% | +6.7% |
| Stockholders Equity | September 30, 2025 | $41.7K | -97.4% | -98.9% |
| R&D Expense | March 31, 2025 | $3.20M | +37.8% | +19.9% |
| Operating Income | September 30, 2025 | -$9.36M | -123.5% | -81.2% |
| Shares Outstanding | September 30, 2025 | 34.45M | +43.7% | +8.3% |
- MAIA Biotechnology, Inc. reported Net Income of -$22.40 million for fiscal year 2025.
- MAIA Biotechnology, Inc. showed an increase of +3.7% in Net Income compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported Diluted EPS of $0.70 per share (loss) for fiscal year 2025.
- MAIA Biotechnology, Inc. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported Total Assets of $9.70 million for fiscal year 2025.
- MAIA Biotechnology, Inc. showed a decrease of -4.4% in Total Assets compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported Stockholders Equity of $2.38 million for fiscal year 2025.
- MAIA Biotechnology, Inc. showed a decrease of -34.6% in Stockholders Equity compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported R&D Expense of $10.01 million for fiscal year 2024.
- MAIA Biotechnology, Inc. showed a decrease of -9.9% in R&D Expense compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported Operating Income of -$24.27 million for fiscal year 2025.
- MAIA Biotechnology, Inc. showed a decrease of -43.1% in Operating Income compared to the prior fiscal year.
- MAIA Biotechnology, Inc. reported Shares Outstanding of 38.62 million shares for fiscal year 2025.
- MAIA Biotechnology, Inc. showed an increase of +47.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: